Vendor source

Reviewed 11 May 2026

Completeness Strong (69%)

AIRAscore structure

AIRAmed

AIRAscore structure provides quantitative data of brain tissue and brain structures for early detection of atrophies and tracking progression. In addition, the lesion characterisation and quantification may support the diagnosis of a wide range of neurodegenerative diseases. The results are presented in the PACS as a PDF report and compared to an age- and sex-correlated reference collective. Bar charts and a pictogram-based spatial representation of the results facilitate their interpretation.

Supported by 1 paper

AIRAscore structure thumbnail 1
AIRAscore structure thumbnail 2
AIRAscore structure thumbnail 3
AIRAscore structure thumbnail 4

Key Features

  • Brain tissue and anatomy segmentation
  • Normative comparison
  • Report generation
  • Volume quantification
  • WMH detection and quantification

General Information

Product name

AIRAscore structure

Company

Modality

MR

Main task

Not specified

Subspeciality

Neuro

Disease targeted

Neurodegenerative diseases, e.g. dementia, Alzheimer’s disease, multiple sclerosis, Parkinson’s Disease

Regulatory Information

CE Certification

Pathway:

MDD

Class:

Class I

Verified by Health AI Register

FDA Certification

Pathway:

510(k) cleared

Class:

Class II

FDA Number:

Verified by Health AI Register

Other certifications

Not specified

Technical Specifications

Patient population age

Not specified

Input

3DT1 MRI, 3D or 2D T2 FLAIR, 1.5 or 3T

Input format

DICOM

Output

Table of quantified values, bar charts and a pictogram-based spatial representation of the values, PDF-report, segmentation overlays

Output format

DICOM, DICOM-PDF

Integration

Integration in standard reading environment (PACS)

Deployment

Cloud-based, Hybrid solution, Locally virtualized (virtual machine, Docker)

Trigger for analysis

On demand, triggered by a user through e.g. a button click, image upload

Processing time

1 - 10 minutes

Population

All with suspicion of or in treatment of neurodegenerative disease

Market Presence

On market since

08-2020

AI Platforms

Resellers

Not specified

Countries present

Not specified

Paying clinical customers

Not specified

Research/test users

Not specified

Pricing Information

Pricing model

Not specified

Based on

Number of analyses

Source: Vendor | First published: Sep 29, 2023 | Last updated: May 11, 2026